From: Evaluation of two strategies for the interpretation of tumour markers in pleural effusions
Single cut-offa | Ratio F/Sb | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Sensitivity | NPV | Specificity | PPV | Accuracy | Sensitivity | NPV | Specificity | PPV | Accuracy | |
CEA | 36.9 | 78.1 | 100.0 | 100.0 | 80.6 | 58.2 | 84.3 | 99.0 | 94.7 | 85.8 |
CA15-3 | 37.7 | 78.5 | 100.0 | 100.0 | 80.9 | 43,7 | 80.2 | 98.6 | 92.9 | 81.6 |
CA72-4 | 32.8 | 77.0 | 100.0 | 100.0 | 79.3 | 36.1 | 78.2 | 100.0 | 100.0 | 80.6 |
CA19-9 | 22.5 | 74.5 | 100.0 | 100.0 | 75.8 | 32.0 | 77.1 | 100.0 | 100.0 | 79.3 |
All TM | 63.9 | 86.4 | 100.0 | 100.0 | 89.3 | 77.0 | 90.7 | 98.2 | 94.7 | 91.0 |
Effusions with ADA < 45U/L; CRP < 50 mg/L and %polymorphonuclear cells <90 | ||||||||||
CEA | 41.7 | 76.9 | 100.0 | 100.0 | 80.2 | 63.1 | 84.0 | 100.0 | 100.0 | 87.2 |
CA15-3 | 38.8 | 76.3 | 100.0 | 100.0 | 79.4 | 43.7 | 77.8 | 100.0 | 100.0 | 81.5 |
CA72-4 | 34.7 | 74.3 | 100.0 | 100.0 | 77.4 | 38.8 | 76.3 | 100.0 | 100.0 | 79.4 |
CA19-9 | 24.8 | 71.6 | 100.0 | 100.0 | 74.1 | 34.0 | 74.8 | 100.0 | 100.0 | 77.7 |
All TM | 69.9 | 86.8 | 100.0 | 100.0 | 89.9 | 80.6 | 91.0 | 100.0 | 100.0 | 93.4 |
Effusions with ADA > 45U/L; CRP > 50 mg/L and/or %polymorphonuclear cells >90 | ||||||||||
CEA | 10.5 | 81.5 | 100.0 | 100.0 | 81.2 | 31.6 | 84.9 | 97.3 | 75.0 | 81.2 |
CA15-3 | 31.6 | 85.1 | 100.0 | 100.0 | 86.2 | 36.8 | 85.9 | 94.5 | 63.6 | 81.0 |
CA72-4 | 18.8 | 82.2 | 100.0 | 100.0 | 85.6 | 21.1 | 83.7 | 100.0 | 100.0 | 84.4 |
CA19-9 | 10.5 | 81.5 | 100.0 | 100.0 | 81.5 | 21.1 | 83.7 | 100.0 | 100.0 | 84.4 |
All TM | 36.8 | 86.5 | 100.0 | 100.0 | 87.5 | 57.9 | 90.0 | 93.5 | 68.8 | 85.5 |